Skip to main content
Clinical Trials/NCT00874796
NCT00874796
Terminated
Phase 2

A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)

Gilead Sciences0 sites307 target enrollmentMay 2009
ConditionsHCV Infection
InterventionsGS-9450Placebo

Overview

Phase
Phase 2
Intervention
GS-9450
Conditions
HCV Infection
Sponsor
Gilead Sciences
Enrollment
307
Primary Endpoint
Histologic response, defined as a >= 2-point decrease in Knodell necroinflammatory score with no concurrent worsening in the Knodell fibrosis score, at Week 24 .
Status
Terminated
Last Updated
12 years ago

Overview

Brief Summary

This is a Phase 2b, randomized, double-blind, parallel-group, placebo-controlled, multicenter study investigating the safety, tolerability and efficacy of two oral doses of GS-9450 in adults with chronic Hepatitis C Virus (HCV). Approximately 240 subjects 18-65 years of age who meet study entry criteria will be randomized (in other words, selected at random, like flipping a coin) to one of three treatment groups (80 subjects per treatment group) as follows:GS-9450 10 mg once daily,GS-9450 40 mg once daily, or matching placebo once daily.

Following randomization, subjects will return within seven business days for a Baseline (Day 1) visit, at which time study medication will be dispensed and subjects will enter a 26 week treatment phase. During the treatment phase, subjects will receive study drug once daily for 24 weeks and then taper off of study drug over the following 2 weeks by receiving study drug once every other day for one week and then every 3 days for one week. Following completion of the treatment phase, subjects will enter a 4-week off-treatment follow-up phase.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
July 2010
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult subjects, ages 18-65
  • Chronic HCV infection, defined as having documented HCV infection (antibody or RNA positivity) at least 6 months prior to Baseline (Day 1) with HCV viremia at screening
  • Screening Knodell necroinflammatory score \>= 3 based on liver biopsy evaluation (as determined by local pathologist) conducted anytime during the 45-day screening period
  • ALT \> the upper limit of the normal range (ULN) but \< 10 X ULN at the screening visit
  • Previously failed pegylated interferon-based HCV therapy in combination with ribavirin therapy, or is unable to tolerate or has contraindications to receiving interferon or ribavirin therapy
  • BMI between 19 and 36 kg/m2 (inclusive)
  • Creatinine clearance \>= 70 mL/min
  • absolute neutrophil count \>= 1000/mm3
  • Hemoglobin \> 10 g/dL
  • Have no clinical or laboratory evidence of hepatic decompensation

Exclusion Criteria

  • Decompensated liver disease
  • Child-Pugh grade B or C cirrhosis
  • Evidence of hepatocellular carcinoma
  • Positive urine drug screen for cocaine or amphetamines
  • Infection with HCV genotype 3
  • Co-infection with hepatitis B virus or human immunodeficiency virus
  • Pancreatitis
  • Recent significant infection or symptoms of infection
  • Autoimmune disorders
  • Any history of seizure

Arms & Interventions

GS-9450 10 mg/day

GS-9450 taken as one 10 mg capsule by mouth once daily

Intervention: GS-9450

GS-9450 40 mg/day

GS-9450 taken as one 40 mg capsule by mouth once daily

Intervention: GS-9450

Placebo

Placebo taken as one placebo capsule by mouth once daily

Intervention: Placebo

Outcomes

Primary Outcomes

Histologic response, defined as a >= 2-point decrease in Knodell necroinflammatory score with no concurrent worsening in the Knodell fibrosis score, at Week 24 .

Time Frame: Week 24 on-treatment

Secondary Outcomes

  • Change (absolute, percent) from baseline in the Knodell necroinflammatory score(Baseline to Week 24)
  • Change (absolute, percent) from pretreatment in alanine aminotransferase (ALT) levels(Baseline to Week 24)
  • Percentage of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities(Up to 24 weeks plus 30 days following the last dose of study drug)
  • Change (absolute, percent) from baseline in cytokeratin-18 caspase cleavage fragment levels(Baseline to Week 24)
  • Change from baseline in hepatic collagen staining area as measured by morphometry of liver biopsy specimens(Baseline to Week 24)
  • Change from baseline in the percent of apoptotic cells(Baseline to Week 24)
  • Change from baseline in percent of anti-M30 monoclonal antibody-positive hepatocytes(Baseline to Week 24)
  • Change From Baseline in HCV RNA(Baseline to to Week 24)

Similar Trials